Oncolytics Biotech Inc. (ONCY) Targets Year-End Interim Data for REO 033

Oncolytics Biotech Inc. said substantially all REO 033 sites are activated, multiple patients are enrolled, and it expects to have sufficient Part A data for an interim update by year-end 2026. FDA alignment suggests a potential accelerated approval path based on ORR.Material DetailsContext by AI A…